Discovery
Optimisation
Pre-clinical
Phase 1
Phase 2
Small molecule, peptide combination treatment, VAL201 peptide repurposed for anti-inflammatory use in combination with complementary generic components.
BlackCat COVID 19 ARDS treatment summary
(1008.48 KB)
Primary indication: Hyperimmune response in patients after SARS-CoV2 infection
Follow-up indications: Sepsis
Patents: PCT patent family application WO/2021/244964
Developed by: Black Cat Bio Limited in partnership with Oncolytika and ValiRx
